Last reviewed · How we verify
rhDNase I
At a glance
| Generic name | rhDNase I |
|---|---|
| Also known as | Pulmozyme |
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion. (PHASE1)
- DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1) (PHASE1)
- rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease (PHASE1, PHASE2)
- Dornase Alpha for the Treatment of COVID-19 (PHASE2)
- Pulmozyme for Sjogren's Associated Cough (PHASE1)
- Pulmozyme in Cystic Fibrosis With Sinusitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhDNase I CI brief — competitive landscape report
- rhDNase I updates RSS · CI watch RSS
- Tel-Aviv Sourasky Medical Center portfolio CI